Table 2.
miRNAs/mRNAs interactions.
| Transcript_id | Regulation | Published association with ALS or other NDDs | Validated target genes |
|---|---|---|---|
| let-7a-5p | Down | ALS (Waller et al., 2017b; Taguchi and Wang, 2018) | HMGA1, MYO1F, PKM, RAB40C |
| let-7d-5p | Down | ALS (Waller et al., 2017a; Taguchi and Wang, 2018) | |
| let-7f-5p | Down | ALS (Waller et al., 2017b) | |
| let-7g-5p | Down | AD (Mendes-Silva et al., 2016) | |
| let-7i-5p | Down | ALS (Waller et al., 2017b; Taguchi and Wang, 2018) | |
| miR-103a-3p | Down | AD (Chang et al., 2017) | |
| miR-106b-3p | Down | ∗ALS (Si et al., 2018); AD (Guo et al., 2017) | |
| miR-128-3p | Down | ALS (Kovanda et al., 2018); MS (Vistbakka et al., 2017) | ABCG1, BAX, CTDSP1, LGALS3 |
| miR-130a-3p | Down | IFITM1, TGFB1 | |
| miR-130b-3p | Down | ALS (Taguchi and Wang, 2018) | SNAI3 |
| miR-144-5p | Down | ALS (Raheja et al., 2018) | |
| miR-148a-3p | Down | ALS (D’Erchia et al., 2017; Waller et al., 2017b) | BAX, ITGA5 |
| miR-148b-3p | Down | MS (Liguori et al., 2018) | ITGA5 |
| miR-15a-5p | Down | ALS (Recabarren-Leiva and Alarcon, 2018) | HMGA1, UCP2 |
| miR-15b-5p | Down | ALS (Waller et al., 2017a) | |
| miR-151a-5p | Down | ALS (Taguchi and Wang, 2018) | ARHGDIA, OTUB1 |
| miR-151b | Down | ||
| miR-16-5p | Down | ALS (Waller et al., 2017b); ∗(Si et al., 2018) | ARHGDIA, HDGF, HMGA1, ZYX |
| miR-181a-2-3p | Down | ||
| miR-182-5p | Down | ALS (D’Erchia et al., 2017); MS (Liguori et al., 2018) | FLOT1, NFKBIB, PFN1, SMARCD3 |
| miR-183-5p | Down | ALS (D’Erchia et al., 2017) | PTPA |
| miR-186-5p | Down | AD (Satoh et al., 2015) | PTTG1 |
| miR-192-5p | Down | ALS (Raheja et al., 2018) | |
| miR-22-3p | Down | ALS (Waller et al., 2017b; Kovanda et al., 2018) | BSG, CD151, LGALS9, PTMS |
| miR-221-3p | Down | ALS (D’Erchia et al., 2017; Di Pietro et al., 2018; Taguchi and Wang, 2018) | BBC3, GRB10 |
| miR-223-3p | Down | MS (Ebrahimkhani et al., 2017) | HAX1, MYL9 |
| miR-23a-3p | Down | ALS (Di Pietro et al., 2018); MS (Ebrahimkhani et al., 2017) | MT2A |
| miR-25-3p | Down | ALS (Taguchi and Wang, 2018); ∗(Si et al., 2018); MS (Liguori et al., 2018) | |
| miR-26a-5p | Down | ALS (Waller et al., 2017b; Di Pietro et al., 2018; Kovanda et al., 2018; Taguchi and Wang, 2018) | HMGA1, ITGA5, PHB, PRKCD |
| miR-26b-5p | Down | AD (Chang et al., 2017) | MIEN1, MT-CO2 |
| miR-27b-3p | Down | ALS (Waller et al., 2017b); ∗(Si et al., 2018) | PHB, PINK1 |
| miR-28-3p | Down | ALS (Waller et al., 2017b); (Kovanda et al., 2018) | |
| miR-30b-5p | Down | ALS (Raheja et al., 2018); MS (Ebrahimkhani et al., 2017) | |
| miR-30c-5p | Down | AD (Satoh et al., 2015) | IER2, VIM |
| miR-342-3p | Down | AD (Wang et al., 2017); MS (Ebrahimkhani et al., 2017) | |
| miR-409-3p | Down | ALS (D’Erchia et al., 2017); MS (Ebrahimkhani et al., 2017) | |
| miR-425-5p | Down | ALS (Raheja et al., 2018) | TACC3 |
| miR-451a | Down | ALS (Taguchi and Wang, 2018); MS (Ebrahimkhani et al., 2017) | CDKN2D |
| miR-532-5p | Down | MS (Selmaj et al., 2017) | |
| miR-550a-3p | Down | MAPK3 | |
| miR-584-5p | Down | ALS (Kovanda et al., 2018; Taguchi and Wang, 2018) | |
| miR-93-5p | Down | ∗ALS (Si et al., 2018) | RHOC |
In the first column (left) are listed those miRNAs that were significantly downregulated in the sALS group compared to HCs (in bold the sRNA-Seq confirmed after qRT-PCR). In the last column (right) we report the correspondent experimentally validated (upregulated) genes resulted from our integrated analysis. In the central column (second from the right) are listed some of the references reporting the association between each miRNA and ALS or other neurodegenerative disease. ∗Data referred to muscles in animal models (mouse).